This includes ATTO-3712, a first-in-class anti-IL13 x IL31, half-life extended bispecific that will be developed for the treatment of atopic dermatitis and other inflammatory conditions; ATTO-004, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback